Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PEPTAVLON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus PEPTAVLON.
AMINOHIPPURATE SODIUM vs PEPTAVLON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Peptavlon is a synthetic analogue of human parathyroid hormone (PTH 1-34) that acts as a diagnostic agent by stimulating osteoblast activity and increasing serum calcium levels through PTH receptor activation.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
Intravenous: 0.5 mg/kg every 6 hours; maximum single dose 40 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life: 8 hours (range 6-10 hours) in adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Renal: 65% (unchanged), Biliary: 25% (metabolites), Fecal: 10%
Category C
Category C
Diagnostic Agent
Diagnostic Agent